Design, synthesis, and pharmacological evaluation of indazole carboxamides of N-substituted pyrrole derivatives as soybean lipoxygenase inhibitors
- PMID: 38145424
- DOI: 10.1007/s11030-023-10775-8
Design, synthesis, and pharmacological evaluation of indazole carboxamides of N-substituted pyrrole derivatives as soybean lipoxygenase inhibitors
Abstract
In this paper, we attempted to develop a novel class of compounds against lipoxygenase, a key enzyme in the biosynthesis of leukotrienes implicated in a series of inflammatory diseases. Given the absence of appropriate human 5-lipoxygenase crystallographic data, solved soybean lipoxygenase-1 and -3 structures were used as a template to generate an accurate pharmacophore model which was further used for virtual screening purposes. Eight compounds (1-8) have been derived from the in-house library consisting of N-substituted pyrroles conjugated with 5- or 6-indazole moieties through a carboxamide linker. This study led to the discovery of hit molecule 8 bearing a naphthyl group with the IC50 value of 22 μM according to soybean lipoxygenase in vitro assay. Isosteric replacement of naphthyl ring with quinoline moieties and reduction of carbonyl carboxamide group resulted in compounds 9-12 and 13, respectively. Compound 12 demonstrated the most promising enzyme inhibition. In addition, compounds 8 and 12 were found to reduce the carrageenan-induced paw edema in vivo by 52.6 and 49.8%, respectively. In view of the encouraging outcomes concerning their notable in vitro and in vivo anti-inflammatory activities, compounds 8 and 12 could be further optimized for the discovery of novel 5-lipoxygenase inhibitors in future.
Keywords: Inflammation; Molecular docking; Pharmacophore model; Pyrrole-indazole derivatives; Soybean lipoxygenase; Virtual screening.
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
Declarations. Conflicts of interest: The authors declare no conflict of interest. Ethical approval: The animal study protocol was approved by the Ethics Committee of the Prefecture of Central Macedonia (protocol code 270079/2500) for studies involving animals. Human and animal rights: No humans were used for studies that are the basis of this research. All the animal experiments complied with the ARRIVE guidelines and were in accordance with the ethical standards of the European Directive 2010/63/EU on the protection of animals used for scientific purposes. Informed consent: Not applicable.
Similar articles
-
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.Bioorg Med Chem. 2017 Aug 15;25(16):4424-4432. doi: 10.1016/j.bmc.2017.06.027. Epub 2017 Jun 16. Bioorg Med Chem. 2017. PMID: 28669741
-
Synthesis of substituted fluorobenzimidazoles as inhibitors of 5-lipoxygenase and soluble epoxide hydrolase for anti-inflammatory activity.Arch Pharm (Weinheim). 2018 Jun;351(6):e1800030. doi: 10.1002/ardp.201800030. Epub 2018 May 7. Arch Pharm (Weinheim). 2018. PMID: 29732612
-
Synthesis, anti-inflammatory, analgesic, 5-lipoxygenase (5-LOX) inhibition activities, and molecular docking study of 7-substituted coumarin derivatives.Bioorg Chem. 2016 Aug;67:130-8. doi: 10.1016/j.bioorg.2016.06.004. Epub 2016 Jun 17. Bioorg Chem. 2016. PMID: 27376460
-
Synthesis and pharmacochemical evaluation of novel aryl-acetic acid inhibitors of lipoxygenase, antioxidants, and anti-inflammatory agents.Bioorg Med Chem. 2007 Sep 1;15(17):5819-27. doi: 10.1016/j.bmc.2007.06.001. Epub 2007 Jun 7. Bioorg Med Chem. 2007. PMID: 17604175
-
Synthesis of phenyl-substituted amides with antioxidant and anti-inflammatory activity as novel lipoxygenase inhibitors.Med Chem. 2007 Mar;3(2):175-86. doi: 10.2174/157340607780059512. Med Chem. 2007. PMID: 17348855 Review.
Cited by
-
Multi-Targeting Valproic Acid Conjugates as Potent Agents Against Inflammation and Hyperlipidemia.Molecules. 2025 May 27;30(11):2339. doi: 10.3390/molecules30112339. Molecules. 2025. PMID: 40509225 Free PMC article.
References
-
- Kotas ME, Medzhitov R (2015) Homeostasis, inflammation, and disease susceptibility. Cell 160:816–827. https://doi.org/10.1016/j.cell.2015.02.010 - DOI - PubMed - PMC
-
- Bennett JM, Reeves G, Billman GE, Sturmberg JP (2018) Inflammation-nature’s way to efficiently respond to all types of challenges: Implications for understanding and managing “the epidemic” of chronic diseases. Front Med 5:1–30. https://doi.org/10.3389/fmed.2018.00316 - DOI
-
- Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L (2017) Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9:7204–7218. https://doi.org/10.18632/oncotarget.23208 - DOI - PubMed - PMC
-
- Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp Mol Med 38:333–347. https://doi.org/10.1038/emm.2006.40 - DOI - PubMed
-
- Wyss-Coray T, Yan F, Lin AHT, Lambris JD, Alexander JJ, Quigg RJ, Masliah E (2002) Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. PNAS 99:10837–10842. https://doi.org/10.1073/pnas.162350199 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical